Management of acute attacks of hereditary angioedema: potential role of icatibant

Figures & data

Figure 1 Improvement of symptom severity at 4 hours and 12 hours (FAST-1 and FAST-2).⁴⁰

Notes: When completing the visual analog score (VAS), the patient is asked to put a mark on a 100 mm line, according to the severity of each symptom. The left end of the line represents absence of the symptom and the right end of the line represents the most severe symptom imaginable. Distance of the mark along the line gives a measure of symptom severity. Triangles represent FAST-1; quadrilaterals represent FAST-2.

Table 1 Recurrent symptoms reported in dose finding pilot study of icatibant⁴³

Patient age (years)/sex	Site of primary attack	Time after administration of icatibant of recurrence (hours)	Severity of recurrence	Site of recurrence
43F	Abdominal	14	Unknown	Abdominal
	Abdominal	17	Unknown	Abdominal
47M	Skin/abdominal	20	Mild	Skin/abdominal
31M	Skin/abdominal	20	Unknown	Skin
53F	Skin (foot)	27	Unknown	Skin (foot)

Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation AgencyCHMP assessment report for Firazyr 11-7-2008. Accessed on October 10, 2009. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/firazyr/H-899-eu6.pdf.

 Google Scholar

BorkKFrankJGrundtBSchlattmannPNussbergerJKreuzWTreatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant)J Allergy Clin Immunol200711961497150317418383

 PubMed Web of Science ®Google Scholar